First-in-class drug approvals vs Alzheimer's disease drug trial starts in China
In 2025, first-in-class drug approvals in China stood at 11, against 16 for alzheimer's disease drug trial starts.
Change the pair
Compare different indicators
The series
Over time
China, spaced by time. Both series are in count, so they share one axis; the legend names each line.
First-in-class drug approvals and Alzheimer's disease drug trial starts
Unit: count · 10 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| First-in-class drug approvals | 2025 | Actual | 11 |
| First-in-class drug approvals | 2024 | Actual | 48 |
| First-in-class drug approvals | 2023 | Actual | 40 |
| First-in-class drug approvals | 2022 | Actual | 21 |
| Alzheimer's disease drug trial starts | 2025 | Actual | 16 |
| Alzheimer's disease drug trial starts | 2024 | Actual | 14 |
| Alzheimer's disease drug trial starts | 2023 | Actual | 5 |
| Alzheimer's disease drug trial starts | 2022 | Actual | 11 |
| Alzheimer's disease drug trial starts | 2021 | Actual | 12 |
| Alzheimer's disease drug trial starts | 2020 | Actual | 6 |
Shared periods
Side by side
4 periods are published for both series in China as annual figures on the same basis. Comparing anything else would mean comparing different periods.
Provenance
Where these numbers come from
First-in-class drug approvals
Number of approved therapeutic drugs featuring a novel biological mechanism of action.
4 observations charted in China · source organisations: NMPA, NHSA
Alzheimer's disease drug trial starts
Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in China · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring